Table 5.
Antipsychotic Drugs Analyzed and the DMEs that Metabolize Them
| Drug | Major DME |
Secondary DME |
Minor DME1 |
Minor DME2 |
Minor DME3 |
Transporter | Glucuronidase | |
|---|---|---|---|---|---|---|---|---|
| 1 | Olanzapine | CYP1A2 | FMO3 | CYP2D6 | CYP3A4 & CYP3A5 |
UGT1A4 | ||
| 2 | Quetiapine | CYP3A4 & CYP3A5 |
CYP2D6 | CYP2C9 | ABCB1 | |||
| 3 | Risperidone | CYP2D6 | CYP3A4 & CYP3A5 |
ABCB1 | ||||
| 4 | Ziprasidone | AOX1* | CYP3A4 & CYP3A5 |
ABCB1 | ||||
| 5 | Perphenazine | CYP2D6 | CYP1A2 | CYP2C9 | CYP2C19 | CYP2C8 |
Abbreviations: DME, drug metabolizing enzyme; CYP, cytochrome P450; AOX1, aldehyde oxidase 1; FMO3, flavin-containing monoxigenase 3; ABCB1, p-glycoprotein (MDR1); UGT1A4, uridine 5′-diphosphate glucuronosyl transferase 1A4.
There are no common functional variants in AOX1 and inhibitors and inducers of the enzyme do not affect ziprasidone pharmacokinetics44,4536, 37. AOX1 was thus not analyzed in this report.